Evidence map›Paper›PMID 39066364›Full record

ArticleVaccines2024

A Live Attenuated H1N1 Influenza Vaccine Based on the Mutated M Gene.

Yinglei Yi, Hongbo Zhang, Youcai An, Ze Chen

Abstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yinglei YiShanghai Institute of Biological Products, Shanghai 200052, China.
Hongbo ZhangDepartment of Basic Research, Ab & B Bio-Tech Co., Ltd. JS, Taizhou 225300, China.
Youcai AnDepartment of Basic Research, Ab & B Bio-Tech Co., Ltd. JS, Taizhou 225300, China.
Ze ChenDepartment of Basic Research, Ab & B Bio-Tech Co., Ltd. JS, Taizhou 225300, China.

Funding

Shanghai Science and Technology Support Program of China 12431901701
6 · The paper itself

Abstract

The influenza vaccines currently approved for clinical use mainly include inactivated influenza virus vaccines and live attenuated influenza vaccines (LAIVs). LAIVs have multiple advantages, such as ease of use and strong immunogenicity, and can provide cross-protection. In this study, the M gene of the PR8 virus was mutated as follows (G11T, C79G, G82C, C85G, and C1016A), and a live attenuated influenza virus containing the mutated M gene was rescued and obtained using reverse genetic technology as a vaccine candidate. The replication ability of the rescued virus was significantly weakened in both MDCK cells and mice with attenuated virulence. Studies on immunogenicity found that 1000 TCID

Indexed as

cross-protectioninfluenza viruslive attenuated vaccineM gene

Identifiers

PMID39066364
PMCPMC11281364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.